Creation of ‘olmesartan’ administration prohibition on chronic malabsorption patients
The antihypertensive olmesartan’s safety issue has been settled by newly creating a measure about prohibition of administration on chronic malabsorption syndrome patients in the approval article of olmesartan.
On the 22nd, the Ministry of Food and Drug Safety(MFDS) announced the notice of change...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
